Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT07394270
Starting soon Phase 2

Effect of Add-on L-Arginine Therapy on Heart Failure Patients

NCT07394270 · tracked via the Priya Life Science Egypt tracker
Sponsor
German University in Cairo
Phase
Phase 2
Started
2026-02
Last updated
2026-02-06

Condition(s) studied

Heart Failure

Investigational drug(s) / intervention(s)

L-Arginine PowderPlacebo

L-Arginine Powder: L-arginine 3 gm sachets are used twice daily

Placebo: 2 sachets of placebo are administered per day

Study summary

Heart failure is considered one of the greatest challenges globally. There are various treatment strategies for heart failure. L-Arginine is an amino acid that was found to have beneficial effect on vasculature. This study aims to study the benefits and side effects of using L-arginine on the patients with ejection fraction \<40%

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with EF \<40% * eGFR \>30 mL/min/1.73 m2 * Stable patients * Capable and willing to provide written consent Exclusion Criteria: * Patients with implantable cardioverter-defibrillator * Pregnant or lactating fmeales * Patients with a history of sensitivity to L-Arginine or any of the excipients * Acute heart failure patients * Patients use L-arginine supplementation. * Patients with active herpes disease

Primary outcome measure(s)

  • Change of Global longitudinal strain value (GLS) of HF patients from the baseline — 6 weeks

Trial sites (1)

FacilityCityRegionStatus
Ain Shams University Cairo Egypt

More German University in Cairo trials in Egypt

Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients Recruiting
L-carnitine Supplementation in Rheumatoid Arthritis Patients Recruiting

Other trials for the same condition

Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction Recruiting
Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF Recruiting
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases Recruiting
AI-Based Personalized Self-Management for Patients With Heart Failure Starting soon
the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07394270 on ClinicalTrials.gov ↗ ← All trials in Egypt